tiprankstipranks
Trending News
More News >
Affluent Partners Holdings (HK:1466)
:1466
Advertisement

Affluent Partners Holdings (1466) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Affluent Partners Holdings

(OTC:1466)

Rating:51Neutral
Price Target:
Affluent Partners Holdings is currently facing significant financial difficulties with declining revenues and negative cash flows. While the technical analysis shows positive price trends, the company's poor valuation metrics highlight a lack of profitability. The main strengths are its moderate leverage and adequate liquidity, which provide some stability. However, the major risks are the ongoing financial losses and lack of earnings visibility, resulting in a low overall score.

Affluent Partners Holdings (1466) vs. iShares MSCI Hong Kong ETF (EWH)

Affluent Partners Holdings Business Overview & Revenue Model

Company DescriptionAffluent Partners Holdings Limited (1466) is a Hong Kong-based investment holding company primarily engaged in the distribution and trading of gemstones and jewelry. The company operates through its subsidiaries, which specialize in the design, sourcing, and distribution of a variety of fine jewelry and precious gemstones. Affluent Partners Holdings aims to leverage its expertise in the luxury goods market by expanding its product offerings and enhancing its distribution network.
How the Company Makes MoneyAffluent Partners Holdings generates revenue mainly through the sale of gemstones and jewelry. The company sources raw gemstones, which are then processed and crafted into fine jewelry pieces, or sold as loose stones to other jewelry manufacturers and retailers. The primary revenue streams include wholesale distribution to retailers and direct sales to consumers through various channels. Strategic partnerships with suppliers and retailers enhance its market reach and distribution capabilities. Additionally, the company may engage in joint ventures or collaborations to expand its product lines and access new markets, contributing to its overall earnings.

Affluent Partners Holdings Financial Statement Overview

Summary
Affluent Partners Holdings faces significant financial challenges, characterized by declining revenues, persistent losses, and negative cash flows. While the balance sheet indicates some financial stability with moderate leverage and adequate liquidity, the company needs to address its profitability issues to improve its overall financial health and support long-term growth.
Income Statement
35
Negative
Affluent Partners Holdings has experienced a significant decline in revenue from the previous year, indicating a negative revenue growth rate. The gross profit margin has improved from previous periods, though the company remains unprofitable with a negative net profit margin and EBIT margin. These factors highlight challenges in achieving profitability and sustainable growth.
Balance Sheet
55
Neutral
The debt-to-equity ratio indicates moderate leverage, but the company has a healthy equity ratio, suggesting stability in its capital structure. However, the negative return on equity reflects ongoing profitability challenges. The balance sheet shows adequate liquidity with sufficient cash reserves to manage short-term liabilities.
Cash Flow
40
Negative
Operating cash flow remains negative, which is concerning for cash generation. There is a slight improvement in free cash flow compared to the previous year, but it remains negative. This underscores the company's struggles in generating positive cash flow from operations, limiting its ability to invest in growth without external financing.
BreakdownMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue53.68M86.88M62.65M43.32M111.98M
Gross Profit18.10M7.83M10.99M-8.62M28.55M
EBITDA-6.32M11.13M-9.73M-45.45M-239.50M
Net Income-7.45M8.73M-15.46M-51.78M-281.82M
Balance Sheet
Total Assets196.80M99.85M82.11M91.77M158.66M
Cash, Cash Equivalents and Short-Term Investments37.88M41.26M23.59M24.42M34.49M
Total Debt51.19M2.76M31.84M31.56M39.50M
Total Liabilities84.01M21.51M46.24M45.82M73.53M
Stockholders Equity96.31M78.34M35.87M45.95M85.13M
Cash Flow
Free Cash Flow-6.64M-21.55M1.06M-16.21M-1.29M
Operating Cash Flow-6.46M-21.52M1.11M-16.18M2.33M
Investing Cash Flow4.74M35.30M-60.00K138.00K39.15M
Financing Cash Flow819.00K3.70M-1.72M6.77M-35.22M

Affluent Partners Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.67
Price Trends
50DMA
0.69
Negative
100DMA
0.65
Positive
200DMA
0.60
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
36.75
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1466, the sentiment is Negative. The current price of 0.67 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.69, and above the 200-day MA of 0.60, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.75 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1466.

Affluent Partners Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
€4.53B9.0511.40%19.05%1.38%-14.80%
61
Neutral
HK$4.67B8.5387.02%2.17%-26.23%147.99%
56
Neutral
HK$25.30B3.94-2.03%6.16%-0.31%-67.70%
51
Neutral
HK$82.79M-1.92%20.02%90.55%
51
Neutral
HK$517.50M-14.00%60.41%-185.00%
45
Neutral
HK$387.76M
4.26%3.24%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1466
Affluent Partners Holdings
0.67
0.07
11.67%
HK:0866
China Qinfa Group Ltd.
1.74
1.01
138.36%
HK:0333
Top Form International Limited
0.28
-0.02
-6.67%
HK:2226
Honworld Group Ltd.
0.67
0.07
11.67%
HK:1234
China Lilang Ltd.
3.77
-0.07
-1.93%

Affluent Partners Holdings Corporate Events

Baijin Life Science Completes New Share Issuance
Apr 3, 2025

Baijin Life Science Holdings Limited has completed the issuance of new shares under a general mandate, resulting in a change in the company’s shareholding structure. The completion of this subscription process on March 28, 2025, has generated net proceeds of approximately HK$31,273,000, which are expected to be used for the general working capital of the group. This move is likely to impact the company’s operational liquidity and market positioning, as it adjusts its shareholding distribution among various stakeholders.

Baijin Life Science Holdings Announces Auditor Change to Baker Tilly
Mar 28, 2025

Baijin Life Science Holdings Limited has announced a change in its auditing firm. Moore CPA Limited has resigned due to a disagreement over audit fees, and Baker Tilly Hong Kong Limited has been appointed as the new auditor. The company assures stakeholders that the change will not impact the audit process or the release of financial results for the period ending March 31, 2025. The Board and Audit Committee believe that Baker Tilly’s appointment will enhance cost-effectiveness and maintain audit quality, benefiting the company and its shareholders.

Baijin Life Science Clarifies Share Subscription Details
Mar 21, 2025

Baijin Life Science Holdings Limited has issued a supplemental announcement regarding the subscription of new shares under a general mandate. The company clarified clerical errors related to the subscription price and provided updates on the shareholding structure, indicating changes in share distribution among subscribers and other stakeholders. The announcement also noted that proceeds from a previous subscription have been fully utilized.

Baijin Life Science Announces New Share Subscription Agreement
Mar 18, 2025

Baijin Life Science Holdings Limited has announced a new share subscription agreement, issuing 65,359,433 new shares at HK$0.48 each, representing approximately 9.24% of its existing share capital. This move, under the General Mandate, aims to enhance the company’s capital base, with the shares to be listed on the Stock Exchange, though completion is contingent on certain conditions being met.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 07, 2025